The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
| Status: | Recruiting |
|---|---|
| Conditions: | Allergy, Sinusitis |
| Therapuetic Areas: | Otolaryngology |
| Healthy: | No |
| Age Range: | 7 - 18 |
| Updated: | 2/21/2019 |
| Start Date: | May 2011 |
| End Date: | June 2019 |
This is a 14-day, randomized, placebo-controlled, parallel group, masked clinical trial of
oral guaifenesin for the therapy of Chronic Rhinitis in 36 children between the ages of 7 and
18 years. The study investigates the effectiveness of guaifenesin in the relief of nasal
symptoms in children with CRS using the sinonasal 5 survey (SN-5) in comparison to nasal
airway volume, and biophysical properties of nasal secretion. The investigators hypothesize
that Guaifenesin use over a period of 14 days improves subjective nasal complaints in
pediatric patients with chronic rhinitis and nasal congestion, as measured by the SN-5 survey
compared to use of placebo. There will be an observed improvement in nasal volume and
cross-sectional area following use of guaifenesin, and nasal secretions will have more
favorable mucociliary and sneeze clearability compared to use of placebo.
oral guaifenesin for the therapy of Chronic Rhinitis in 36 children between the ages of 7 and
18 years. The study investigates the effectiveness of guaifenesin in the relief of nasal
symptoms in children with CRS using the sinonasal 5 survey (SN-5) in comparison to nasal
airway volume, and biophysical properties of nasal secretion. The investigators hypothesize
that Guaifenesin use over a period of 14 days improves subjective nasal complaints in
pediatric patients with chronic rhinitis and nasal congestion, as measured by the SN-5 survey
compared to use of placebo. There will be an observed improvement in nasal volume and
cross-sectional area following use of guaifenesin, and nasal secretions will have more
favorable mucociliary and sneeze clearability compared to use of placebo.
Inclusion Criteria:
- Children between the ages of 7 and 18 years, diagnosed with Chronic Rhinitis and nasal
stuffiness for at least 3 month duration.
Exclusion Criteria:
- Children with immunodeficiency, cystic fibrosis, acute or subacute symptoms, signs of
bacterial infection, and/or those who are unable to cooperate with testing will be
excluded. Children with documented use of the study medication in the month before
evaluation and during period of symptoms will also be excluded.
We found this trial at
1
site
Richmond, Virginia 23298
Principal Investigator: Kelley Dodson, MD
Phone: 804-828-3965
Click here to add this to my saved trials
